Critical Outcome Technologies Inc. home page
COTI Home page COTI Products Partnering with COTI COTI Discovery Process Investor Relations at COTI About COTI Contact COTI


Critical Outcome Technologies Inc. (COTI) is helping the pharmaceutical industry get novel treatments to market faster.

At COTI’s core is a proprietary technology called CHEMSAS® that rapidly accelerates drug discovery. COTI is able to discover, profile, optimize, synthesize and validate novel compounds in 12-15 months. The current industry approach can take up to 60 months.

Our products are targeted libraries of novel, optimized lead compounds for the treatment of human diseases for which current therapy is either lacking or ineffective. Learn more about our products in development.

Visit our partnering page if you are interested in augmenting your existing pipeline or developing a pipeline in areas of interest and reducing the cost of drug discovery.

 

07.02.09

Intravenous COTI-2 in Combination with DoxilŽ (Doxorubicin HCL) is More Effective than Treatment with Doxil Alone in an Animal Model of Human Ovarian Cancer

06.10.09

Critical Outcome Technologies Inc. Announces Private Placement

05.14.09

COTI-2 in Combination with TaxolŽ (Paclitaxel) is Superior to Treatment with Paclitaxel Alone in an Animal Model of Aggressive Human Endometrial Cancer

 

Our Products

Become a Partner

Investor News

Careers

 
© 2008 Critical Outcome Technologies Inc. All rights reserved.